ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.Neurology and therapy · 2026Review
- Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.Journal of neurology, neurosurgery, and psychiatry · 2026Observational
- De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: An initial Iranian experience.Caspian journal of internal medicine · 2025Article
- Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.Scientific reports · 2024Article
- Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy.Drug design, development and therapy · 2024Review
- Should anti-CD20 be used as an immune reconstitution therapy?Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.